Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EYLEA in neovascular age-related macular degeneration
NCT00527423Phase 2Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Aug 2007
- Primary completion
- Oct 2011
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of aflibercept in neovascular age-related macular degeneration (NVAMD), sponsored by Regeneron Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events at 152 weeks. Started Aug 2007; status: completed.
02
Drugs
aflibercept
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT00527423.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00527423.